METF LOZA

About METF LOZA

Youre referring to a combination medication that contains: Metformin Hydrochloride (Extended Release - ER) Glimepiride Pioglitazone These three are oral antidiabetic agents, commonly used together in the treatment of Type 2 Diabetes Mellitus (T2DM).Breakdown of the Ingredients: 1. Metformin Hydrochloride (ER) Class: Biguanide Action: Decreases hepatic glucose production Increases insulin sensitivity Improves peripheral glucose uptake Extended-release (ER) formulation helps reduce gastrointestinal side effects and allows once-daily dosing. 2. Glimepiride Class: Sulfonylurea Action: Stimulates the pancreas to release more insulin Works best when some pancreatic function is preserved 3. Pioglitazone Class: Thiazolidinedione (TZD) Action: Improves insulin sensitivity in muscle and adipose tissue Reduces insulin resistance Therapeutic Use: This combination is typically prescribed when diet and exercise alone and/or monotherapy with a single oral agent does not provide adequate blood sugar control. It offers a multifaceted approach to manage blood glucose levels.Common Brand Names(In some countries/formulations, this combo is available under names like): Trimetazidine (note: confirm with local listings) Tripill MGP (generic) But combinations and brand names may vary by country. Important Considerations: Side Effects: Metformin: GI upset, lactic acidosis (rare) Glimepiride: Hypoglycemia, weight gain Pioglitazone: Weight gain, fluid retention, risk of heart failure, possible bladder cancer risk (long-term) Contraindications: Renal impairment (especially for metformin) Heart failure (pioglitazone) Liver disease Hypersensitivity to sulfonylureas (glimepiride) Monitoring: HbA1c levels (every 36 months) Kidney and liver function tests Signs of hypoglycemia or fluid retention